$9.26
-0.04-0.43%
Últ. Act.: Nov 19, 10:00 AM

The average analyst price target for Climb Bio is $25.13, 171.4% above the current price. Of 16 analysts, 16 rate it Buy. Targets range from $9 to $35. The latest change came on Nov 6, 2026, when Wedbush raised its price target on Climb Bio from $25 to $27 and kept an Outperform rating.
Price Target Range — 7 Quarters
Analyst Consensus — 16 Analysts
Rating Trend — Last 9 Months